Effects of Iranian propolis on glycemic status, inflammatory factors, and liver enzyme levels in type 2 diabetic patients: a randomized, double-blind, placebo-controlled, clinical trial
,
Abstract
Objective: Propolis is one of the hive products with a wide clinical usage due to the variety of bioactive components. This clinical trial was conducted to evaluate the effects of propolis supplementation on glycemic status and inflammation.
Methods: In an 8-week randomized, double-blinded, placebo-controlled, clinical trial, patients with type 2 diabetes were randomly assigned to the propolis (n = 31) or control group (n = 31). The first group received propolis capsules (500 mg), 3 times a day. Fasting blood samples were obtained. The liver enzymes, inflammatory markers, and glucose-related indicators were measured at the beginning and the end of the study.
Results: Compared with the control group, the propolis group showed significant changes in fasting plasma glucose (propolis, -19.8 ± 29.16; placebo, 0.7 ± 27.8; p = 0.01), two-hour postprandial glucose (propolis, -27.42 ± 44.5; placebo, -0.95 ± 42.7; p = 0.001), hemoglobin A1c (propolis, -1.07 ± 1.6; placebo, 0.03 ± 1.5; p = 0.041), insulin (propolis, -1.65 ± 4.3; placebo, 0.04 ± 4.02; p = 0.03), HOMA-IR (propolis, -1.08 ± 0.7; placebo, 0.03 ± 0.42; p = .044), TNF-α (propolis, -2.67 ± 4.1; placebo, 0.12 ± 4; p = 0.025), and C-reactive protein (propolis, -2.5 ± 3.01; placebo, -0.67 ± 2.84; p = 0.031). Furthermore, propolis reduced the mean aspartate aminotransferase (AST) (propolis, -1.62 ± 10.4; placebo, 0.13 ± 11.07; p = 0.12) and alanine aminotransferase (ALT) levels (propolis, -0.61 ± 6.47; placebo, 0.12 ± 7.01; p = 0.54), but it was not significant.
Conclusion: Propolis treatment in type 2 diabetic patients had a beneficial effect on the glycemic profile and inflammatory status. However, there was no significant change in the level of AST and ALT enzymes, warranting further research.
Organization WH. Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation. Part 1, Diagnosis and classification of diabetes mellitus. 1999.
Guariguata L, Whiting D, Hambleton I, Beagley J, Linnenkamp U, Shaw J. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes research and clinical practice. 2014;103(2):137-49.
Atlas ID. Brussels, Belgium: International Diabetes Federation; 2013. International Diabetes Federation (IDF). 2014.
Penckofer S, Schwertz D, Florczak K. Oxidative stress and cardiovascular disease in type 2 diabetes: the role of antioxidants and pro-oxidants. Journal of Cardiovascular Nursing. 2002;16(2):68-85.
Strachan MW, Frier BM. Side-Effects of Insulin. Insulin Therapy: Springer; 2013. p. 43-50.
Coman C, Rugina OD, Socaciu C. Plants and natural compounds with antidiabetic action. Notulae Botanicae Horti Agrobotanici Cluj-Napoca. 2012;40(1):314.
Li Y, Chen M, Xuan H, Hu F. Effects of encapsulated propolis on blood glycemic control, lipid metabolism, and insulin resistance in type 2 diabetes mellitus rats. Evidence-based complementary and alternative medicine. 2011;2012.
Huang S, Zhang C-P, Wang K, Li GQ, Hu F-L. Recent advances in the chemical composition of propolis. Molecules. 2014;19(12):19610-32.
Hu F, Hepburn H, Li Y, Chen M, Radloff S, Daya S. Effects of ethanol and water extracts of propolis (bee glue) on acute inflammatory animal models. Journal of Ethnopharmacology. 2005;100(3):276-83.
Wang K, Ping S, Huang S, Hu L, Xuan H, Zhang C, et al. Molecular mechanisms underlying the in vitro anti-inflammatory effects of a flavonoid-rich ethanol extract from Chinese propolis (poplar type). Evidence-Based Complementary and Alternative Medicine. 2013;2013.
Xuan H, Zhao J, Miao J, Li Y, Chu Y, Hu F. Effect of Brazilian propolis on human umbilical vein endothelial cell apoptosis. Food and chemical toxicology. 2011;49(1):78-85.
Lisbona C, Díaz-Castro J, Alférez MJ, Guisado IM, Guisado R, López-Aliaga I. Positive influence of a natural product as propolis on antioxidant status and lipid peroxidation in senescent rats. Journal of physiology and biochemistry. 2013;69(4):919-25.
Silva JC, Rodrigues S, Feás X, Estevinho LM. Antimicrobial activity, phenolic profile and role in the inflammation of propolis. Food and Chemical Toxicology. 2012;50(5):1790-5.
Freires IA, Queiroz VCPP, Furletti VF, Ikegaki M, de Alencar SM, Duarte MCT, et al. Chemical composition and antifungal potential of Brazilian propolis against Candida spp. Journal de Mycologie Médicale/Journal of Medical Mycology. 2016;26(2):122-32.
Azab A, Algridi MA, Lashkham NM. Hypolipidemic and antiatherogenic effects of aqueous extract of Libyan propolis in lead acetate intoxicated male albino mice. IJSR. 2015;4(3):1060-8.
Chan GC-F, Cheung K-W, Sze DM-Y. The immunomodulatory and anticancer properties of propolis. Clinical reviews in allergy & immunology. 2013;44(3):262-73.
Samadi N, Mozaffari-Khosravi H, Rahmanian M, Askarishahi M. Effects of bee propolis supplementation on glycemic control, lipid profile and insulin resistance indices in patients with type 2 diabetes: a randomized, double-blind clinical trial. Journal of Integrative Medicine. 2017;15(2):124-34.
Wang K, Zhang J, Ping S, Ma Q, Chen X, Xuan H, et al. Anti-inflammatory effects of ethanol extracts of Chinese propolis and buds from poplar (Populus× canadensis). Journal of Ethnopharmacology. 2014;155(1):300-11.
Zhu W, Li Y-H, Chen M-L, Hu F-L. Protective effects of Chinese and Brazilian propolis treatment against hepatorenal lesion in diabetic rats. Human & experimental toxicology. 2011;30(9):1246-55.
Zhao L, Pu L, Wei J, Li J, Wu J, Xin Z, et al. Brazilian green propolis improves antioxidant function in patients with type 2 diabetes mellitus. International journal of environmental research and public health. 2016;13(5):498.
Bankova V. Chemical diversity of propolis and the problem of standardization. Journal of ethnopharmacology. 2005;100(1):114-7.
Karunakaran U, Park K-G. A systematic review of oxidative stress and safety of antioxidants in diabetes: focus on islets and their defense. Diabetes & metabolism journal. 2013;37(2):106-12.
Aouacheri O, Saka S, Krim M, Messaadia A, Maidi I. The investigation of the oxidative stress-related parameters in type 2 diabetes mellitus. Canadian journal of diabetes. 2015;39(1):44-9.
Gao J, Koshio S, Ishikawa M, Yokoyama S, Mamauag REP. Interactive effects of vitamin C and E supplementation on growth performance, fatty acid composition and reduction of oxidative stress in juvenile Japanese flounder Paralichthys olivaceus fed dietary oxidized fish oil. Aquaculture. 2014;422:84-90.
Jarouliya U, Zacharia A, Keservani RK, Prasad GB. Spirulina maxima and its effect on antioxidant activity in fructose induced oxidative stress with histopathological observations. Acta Facultatis Pharmaceuticae Universitatis Comenianae. 2015;62(2):13-9.
Sadek KM, Lebda MA, Nasr SM, Shoukry M. Spirulina platensis prevents hyperglycemia in rats by modulating gluconeogenesis and apoptosis via modification of oxidative stress and MAPK-pathways. Biomedicine & Pharmacotherapy. 2017;92:1085-94.
Mujica V, Orrego R, Pérez J, Romero P, Ovalle P, Zúñiga-Hernández J, et al. The Role of Propolis in Oxidative Stress and Lipid Metabolism: A Randomized Controlled Trial. Evidence-Based Complementary and Alternative Medicine. 2017;2017.
Sies H, Cadenas E, Symons M, Scott G. Oxidative stress: damage to intact cells and organs. Philosophical transactions of the Royal Society of London Series B, Biological sciences. 1985:617-31.
Kismet K, Ozcan C, Kuru S, Celemli OG, Celepli P, Senes M, et al. Does propolis have any effect on non-alcoholic fatty liver disease? Biomedicine & Pharmacotherapy. 2017;90:863-71.
Schmidt MI, Duncan BB, Sharrett AR, Lindberg G, Savage PJ, Offenbacher S, et al. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. The Lancet. 1999;353(9165):1649-52.
Duncan BB, Schmidt MI, Pankow JS, Ballantyne CM, Couper D, Vigo A, et al. Low-grade systemic inflammation and the development of type 2 diabetes. Diabetes. 2003;52(7):1799-805.
Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. Jama. 2001;286(3):327-34.
Barzilay JI, Abraham L, Heckbert SR, Cushman M, Kuller LH, Resnick HE, et al. The relation of markers of inflammation to the development of glucose disorders in the elderly. Diabetes. 2001;50(10):2384-9.
Festa A, D’Agostino R, Tracy RP, Haffner SM. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes. Diabetes. 2002;51(4):1131-7.
Freeman DJ, Norrie J, Caslake MJ, Gaw A, Ford I, Lowe GD, et al. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes. 2002;51(5):1596-600.
Spranger J, Kroke A, Möhlig M, Hoffmann K, Bergmann MM, Ristow M, et al. Inflammatory cytokines and the risk to develop type 2 diabetes. Diabetes. 2003;52(3):812-7.
Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 1993;259(5091):87-91.
Feinstein R, Kanety H, Papa M, Lunenfeld B, Karasik A. Tumor necrosis factor-alpha suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates. Journal of Biological Chemistry. 1993;268(35):26055-8.
Hotamisligil GS, Spiegelman BM. Tumor necrosis factor α: a key component of the obesity-diabetes link. Diabetes. 1994;43(11):1271-8.
| Files | ||
| Issue | Vol 3, No 2 (Spring 2017) | |
| Section | Original Article(s) | |
| Keywords | ||
| type 2 diabetes glucose metabolism inflammation antioxidant | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
